Penta-1,2,3,4,6-O-galloyl-β-D-glucose induces p53 and inhibits STAT3 in prostate cancer cells in vitro and suppresses prostate xenograft tumor growth in vivo

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 2681-2691

  Hu, Hongbo ^a   Lee, Hyo Jeong ^a,b   Jiang, Cheng ^a   Zhang, Jinhui ^a   Wang, Lei ^a   Zhao, Yan ^a   Xiang, Qiu ^a   Lee, Eun Ok ^b   Kim, Sung Hoon ^a,b   Lü, Junxuan ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CASPASE; GLUCOSE DERIVATIVE; PENTA 1,2,3,4,6 O GALLOYL BETA DEXTRO GLUCOSE; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN BAK; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR BIOLOGY; MOUSE; MUTANT; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; WILD TYPE;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-X PROTEIN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL-FREE SYSTEM; G1 PHASE; HUMANS; HYDROGEN PEROXIDE; HYDROLYZABLE TANNINS; INTERLEUKIN-6; INTRACELLULAR SPACE; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; S PHASE; STAT3 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54049099288     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0456     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Klein EA. Chemoprevention of prostate cancer. Annu Rev Med 2006;57:49-63.
3. Sarkar FH, Li Y. Cell signaling pathways altered by natural chemopreventive agents. Mutat Res 2004;555:53-64.
4. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19:6613-26.
5. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397-421.
6. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
7. Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. Curr Opin Oncol 2008;20:90-6.
8. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, Mukhtar H. Role of p53 and NF-κB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 2003;22:4851-9.
9. She QB, Bode AM, Ma WY, Chen NY, Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res 2001;61:1604-10.
10. 2 phase of cell cycle in a p53-dependent manner. J Biol Chem 2005;280:20059-68.
11. Zhong Z, Wen Z, Darnell JE, Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994;264:95-8.
12. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
13. Wen Z, Zhong Z, Darnell JE, Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995;82:241-50.
14. Lassmann S, Schuster I, Walch A, et al. STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation. J Clin Pathol 2007;60:173-9.
15. Lin J, Tang H, Jin X, Jia G, Hsieh JT. p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. Oncogene 2002;21:3082-8.
16. Mora LB, Buettner R, Seigne J, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002;62:6659-66.
17. Barton BE, Murphy TF, Shu P, Huang HF, Meyenhofer M, Barton A. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol Cancer Ther 2004;3:1183-91.
18. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003;9:370-6.
19. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 2000;42:186-95.
20. Pu YS, Hour TC, Chuang SE, Cheng AL, Lai MK, Kuo ML. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate 2004;60:120-9.
21. Lambert JD, Yang CS. Cancer chemopreventive activity and bioavailability of tea and tea polyphenols. Mutat Res 2003;523-524:201-8.
22. Lee HH, Ho CT, Lin JK. Theaflavin-3,3′-digallate and penta-O-galloyl-β-D-glucose inhibit rat liver microsomal 5α-reductase activity and the expression of androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 2004;25:1109-18.
23. Chen WJ, Chang CY, Lin JK. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the downregulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip). Biochem Pharmacol 2003;65:1777-85.
24. Hua KT, Way TD, Lin JK. Pentagalloylglucose inhibits estrogen receptor α by lysosome-dependent depletion and modulates ErbB/PI3K/Akt pathway in human breast cancer MCF-7 cells. Mol Carcinog 2006;45:551-60.
25. Ho LL, Chen WJ, Lin-Shiau SY, Lin JK. Penta-O-galloyl-β- D-glucose inhibits the invasion of mouse melanoma by suppressing metalloproteinase-9 through down-regulation of activator protein-1. Eur J Pharmacol 2002;453:149-58.
26. Huh JE, Lee EO, Kim MS, et al. Penta-O-galloyl-β-D- glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways. Carcinogenesis 2005;26:1436-45.
27. Pan MH, Lin-Shiau SY, Ho CT, Lin JH, Lin JK. Suppression of lipopolysaccharide-induced nuclear factor-κB activity by theaflavin-3,3′-digallate from black tea and other polyphenols through down-regulation of IκB kinase activity in macrophages. Biochem Pharmacol 2000;59:357-67.
28. Jiang C, Wang Z, Ganther H, Lu J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001;61:3062-70.
29. Hu H, Jiang C, Ip C, Rustum YM, Lu J. Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res 2005;11:2379-88.
30. Narayanan PK, Goodwin EH, Lehnert BE. a Particles initiate biological production of superoxide anions and hydrogen peroxide in human cells. Cancer Res 1997;57:3963-71.
31. Rothe G, Valet G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2′,7′-dichlorofluorescin. J Leukoc Biol 1990;47:440-8.
32. Hu H, Jiang C, Schuster T, Li GX, Daniel PT, Lu J. Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway. Mol Cancer Ther 2006;5:1873-82.
33. Li GX, Hu H, Jiang C, Schuster T, Lu J. Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells. Int J Cancer 2007;120:2034-43.
34. Nakagawa H, Hasumi K, Woo JT, Nagai K, Wachi M. Generation of hydrogen peroxide primarily contributes to the induction of Fe(II)-dependent apoptosis in Jurkat cells by (-)-epigallocatechin gallate. Carcinogenesis 2004;25:1567-74.
35. Kern M, Fridrich D, Reichert J, et al. Limited stability in cell culture medium and hydrogen peroxide formation affect the growth inhibitory properties of delphinidin and its degradation product gallic acid. Mol Nutr Food Res 2007;51:1163-72.
36. Lee KW, Hur HJ, Lee HJ, Lee CY. Antiproliferative effects of dietary phenolic substances and hydrogen peroxide. J Agric Food Chem 2005;53:1990-5.
37. Agarwal C, Tyagi A, Agarwal R. Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells. Mol Cancer Ther 2006;5:3294-302.
38. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci 2003;116:4077-85.
39. 1 arrest. Cell 1994;76:1013-23.
40. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
41. Nesslinger NJ, Shi XB, deVere White RW. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res 2003;63:2228-33.
42. van Bokhoven A, Varella-Garcia M, Korch C, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-25.
43. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001;159:2159-65.
44. Flowers LO, Subramaniam PS, Johnson HM. A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene 2005;24:2114-20.
45. Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 2006;27:1-22.
46. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther 2002;1:226-31.
47. Chen T, Wang LH, Farrar WL. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 2000;60:2132-5.
48. Lee SO, Lou W, Johnson CS, Trump DL, Gao AC. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate 2004;60:178-86.